Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition.

Science advances - 13 Dec 2024

Song Xinxin, Zhou Zhuan, Elmezayen Ammar, Wu Runliu, Yu Chunhua, Gao Boning, Minna John D, Westover Kenneth D, Zeh Herbert J, Kroemer Guido, Heasley Lynn E, Kang Rui, Tang Daolin

Abstract excerpt

Direct targeting of the KRAS-G12C-mutant protein using covalent inhibitors (G12Ci) acts on human non-small cell lung cancer (NSCLC). However, drug resistance is an emerging concern in this approach. Here, we show that MRTX849, a covalent inhibitor targeting the KRAS-G12C mutation, leads to the reactivation of the mitogen-activated protein kinase signaling pathway in MRTX849-resistant NSCLC and pancreatic ductal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dasatinib
Share to Drug Resistance, Multiple

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-jun

Share to Proto-Oncogene Proteins p21(ras)

Share to src-Family Kinases

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 39661665
DOI: 10.1126/sciadv.adq4274
PMCID: PMC11633746

Genes

KRAS
SRC
ABCC1
JUN

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition.PMID 39661665Read ↗

Acquired Resistance to KRASG12C Inhibition in Cancer.Semantic proximity Read ↗

Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor.Semantic proximity Read ↗

MRTX1133 is a potent non-covalent KRAS (G12C) inhibitor with tissue-specific activitySemantic proximity Read ↗

JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRASG12C for the Treatment of Solid Tumors.Semantic proximity Read ↗

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.Semantic proximity Read ↗

A Non-covalent KRASG12D Allele Specific Inhibitor Demonstrates Potent Inhibition of KRAS-dependent Signaling and Regression of KRASG12D-mutant TumorsSemantic proximity Read ↗

Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy.Semantic proximity Read ↗

Chaperone directed heterobifunctional molecules circumvent KRASG12C inhibitor resistance.Semantic proximity Read ↗

Direct K-Ras Inhibitors to Treat Cancers: Progress, New Insights, and Approaches to Treat Resistance.Semantic proximity Read ↗

Targeting Krasg12c -mutant cancer with a mutation-specific inhibitor.Semantic proximity Read ↗

CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Pharmacologically targeting KRAS <sup>G12D</sup> in PDAC models: tumor cell intrinsic and extrinsic impactSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.